Tonix Pharmaceuticals is currently recruiting participants in a Phase 3 trial for military-related posttraumatic stress disorder.  For more information, please visit www.thehonorstudy.com or www.clinicaltrials.gov (NCT03062540).

Financial Info : Financials

Financials

v3.5.0.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 15,644 $ 19,175
Marketable securities-available for sale, at fair value 11,094 23,841
Prepaid expenses and other 2,483 3,343
Total current assets 29,221 46,359
Property and equipment, net 315 350
Restricted cash 89 132
Intangible asset 120 120
Security deposits 56 57
Total assets 29,801 47,018
Current liabilities:    
Accounts payable 944 3,049
Accrued expenses 1,676 3,601
Total current liabilities 2,620 6,650
Deferred rent payable 76 106
Total liabilities 2,696 6,756
Commitments (See Note 7)
Stockholders' equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized, none issued or outstanding
Common stock, $0.001 par value; 150,000,000 shares authorized; 29,352,718 and 18,831,669 shares issued and outstanding as of September 30, 2016 and December 31, 2015, respectively, and 17,595 shares to be issued as of December 31, 2015 29 19
Additional paid in capital 160,823 142,658
Accumulated deficit (133,758) (102,398)
Accumulated other comprehensive income (loss) 11 (17)
Total stockholders' equity 27,105 40,262
Total liabilities and stockholders' equity $ 29,801 $ 47,018
v3.5.0.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
COSTS AND EXPENSES:        
Research and development $ 5,466 $ 10,314 $ 23,653 $ 26,014
General and administrative 2,143 2,966 7,806 8,746
Total costs and expenses 7,609 13,280 31,459 34,760
Operating loss (7,609) (13,280) (31,459) (34,760)
Interest income, net 31 30 99 66
NET LOSS $ (7,578) $ (13,250) $ (31,360) $ (34,694)
Net loss per common share, basic and diluted (in dollars per share) $ (0.29) $ (0.72) $ (1.45) $ (2.15)
Weighted average common shares outstanding, basic and diluted (in shares) 26,131,085 18,423,816 21,601,574 16,103,382
v3.5.0.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (31,360) $ (34,694)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 163 90
Stock-based compensation 2,367 3,384
Changes in operating assets and liabilities:    
Prepaid expenses 867 (1,290)
Accounts payable (2,114) 948
Accrued expenses (1,725) 948
Deferred rent payable (70) (2)
Net cash used in operating activities (31,872) (30,616)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of furniture and fixtures (66) (68)
Maturities of marketable securities 12,715
Purchase of marketable securities (22,058)
Proceeds from restricted cash 44
Purchase of intangible asset (120)
Net cash provided by (used in) investing activities 12,693 (22,246)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from exercise of warrants 9
Proceeds, net of expenses of $1,294 and $2,115 from sale of common stock 15,641 47,685
Net cash provided by financing activities 15,641 47,694
Effect of currency rate change on cash 7 (7)
Net decrease in cash and cash equivalents (3,531) (5,175)
Cash and cash equivalents, beginning of the period 19,175 38,184
Cash and cash equivalents, end of period 15,644 33,009
Non-cash financing activities:    
Issuance of common stock under employee benefit plan $ 167 $ 160